| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -37.8 | -23.3 |
| EPS (diluted, $ a share) | $-1.81 | $-1.90 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CRBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Corbus Pharmaceuticals Holdings, Inc.: key numbers
- Share price
- $3.38Close, Nov 16
- Market cap
- $69.5M
- Shares outstanding
- 20.61MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Corbus Pharmaceuticals Holdings, Inc.
All →Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.
- Term
- 16 weeks
“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
Corbus Pharmaceuticals Holdings Financial Results
Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.
“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
Corbus Pharmaceuticals Holdings Insider Cormorant Asset Management LP Sells $1.74M of Stock
Cormorant Asset Management LP sold 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. at $4.10 a share, worth $1.74M in total on Oct 29, 2026. Shares held after the trade: 1,919,971 (-18.1%).
- Value
- $1.74M
- Shares
- 425,000
- Price
- $4.10
- Holding change
- -18.1%
- Trade date
- Oct 29, 2026
Corbus Pharmaceuticals Holdings Investor Presentation
Corbus Pharmaceuticals updated its corporate investor presentation to highlight its clinical pipeline in oncology and obesity. Key focus areas include the CRB-701 Nectin-4 ADC, which is entering a registrational Phase 2 study for OPSCC, and CRB-913, a CB1 inverse agonist for obesity with a Phase 2 study expected to start in the first half of 2027.
Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The study met its primary objectives, demonstrating statistically significant weight loss of 5% at the 60 mg dose over 12 weeks with a favorable safety profile and no evidence of weight loss plateauing. The data supports CRB-913's potential as a first-in-class oral, non-incretin obesity medicine.
- Term
- 16 weeks
- Earnings call
- Sep 14, 2026, 8:00 AM ET